• Tositumomab and Iodine I 131 Tositumomab - upmc.com

    The drug tositumomab and iodine I 131 tositumomab is used to treat cancer. It is a combination of tositumomab, a special type of antibody used to treat cancer, and iodine I 131, a radioactive element that has been shown to be effective against cancer.

  • Definition of tositumomab and iodine I 131 tositumomab ...

    A murine IgG2a lambda monoclonal antibody, both unradiolabeled and radiolabeled with iodine I 131, directed against the human B cell-specific surface antigen CD20. Tositumomab binds to CD20, resulting in complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis in B cells expressing CD20; in addition to the antibody-mediated cytotoxicity, iodine I ...

  • BEXXAR ----------------------- WARNINGS AND PRECAUTIONS

    BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directed radiotherapeutic antibody indicated for the treatment of patients with CD20- positive, …

  • Bexxar - FDA prescribing information, side effects and uses

    Tositumomab is a monoclonal antibody that is linked with radioactive iodine I-131. Monoclonal antibodies are made to target and destroy only certain cells in the body.

  • Talk:Tositumomab - Wikipedia

    Was Tositumomab ever used without iodine 131. How were they combined ? - Rod57 19:52, 18 January 2016 (UTC) good question. i didn't know how this was drug was used and it was fun to learn. pls let me know if the article now answers your question. Jytdog 20:44, 18 January 2016 (UTC)

  • tositumomab and Iodine 131 - news.cancerconnect.com

    Jun 01, 2018· Tositumomab and I131 tositumomab are administered into a vein (intravenous). The regimen is administered in two steps; the dosimetric step, in which the therapeutic dose is determined, and the therapeutic step, where the patient actually receives the dose for treatment. Each step consists of administration of tositumomab followed by I131 ...

  • Iodine-131 Tositumomab | SpringerLink

    Aug 16, 2012· Kaminski M, Estes J, Regan D, et al. Retreatment with Bexxar™ (tositumomab and iodine-131 tositumomab) for patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. 37th Annual Meeting of the American Society of Clinical Oncology 20: 285, Pt 1, …

  • Tositumomab

    Jun 12, 2015· Tositumomab was previously available in liquid solution in single use vials of 35 and 225 mg (14 mg/mL) and as Iodine 131 tositumomab solutions of varying concentrations. Dosing required a 2 part dosimetric step followed 7 to 14 days later by a 2-part therapeutic step. Tositumomab was meant to be given only for a single course.

  • Tositumomab | definition of tositumomab by Medical dictionary

    tositumomab (I 131 tositumomab) (to-si- too -mo-mab) , Bexxar (trade name) Classification Therapeutic: antineoplastics Pharmacologic: monoclonal antibodies Pregnancy Category: X Indications CD20 positive, follicular, non-Hodgkin's lymphoma refractory to rituximab and in relapse. Action genetic implication Binds to CD20 antigens on the surface ...

  • Iodine131 tositumomab (Bexxar) | CancerIndex

    Two radioimmunoconjugates--yttrium-90 ibritumomab tiuxetan (Zevalin) and iodine-131 tositumomab (Bexxar) have been in clinical use. There are multiple studies demonstrating the safety and efficacy of both agents in both indolent and aggressive lymphoma. Radiolabeled antibodies are ideal candidates to combine with high-dose chemotherapy and ASCT.

  • Iodine I 131/tositumomab: Indications, Side Effects ...

    Keep iodine I 131/tositumomab out of reach of children and away from pets. General information: If you have any questions about iodine I 131/tositumomab, please talk with your doctor, pharmacist, or other health care provider. Iodine I 131/tositumomab is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • A phase 2 trial of CHOP chemotherapy ... - Blood Journal

    Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial (S9911) of a novel regimen consisting of 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I 131 tositumomab (anti-CD20 antibody) in 90 eligible ...

  • Tositumomab and iodine I-131 - ONS

    Tositumomab 450 mg IV over 60 minutes. Iodine-131 at precalculated dose and 35 mg tositumomab IV over 20 minutes. Tositumomab labeled with Iodine I-131 dose as determined by dosimetric dose given 7–14 days following dosimetric dose. Physician must be certified in initial dose determinations before calculating doses independently. Indications

  • Tositumomab and Iodine I 131 Tositumomab (Bexaar ...

    SUMMARY: Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.

  • tositumomab - CardioSmart

    Tositumomab is a monoclonal antibody that is linked with radioactive iodine I-131. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tositumomab is used to treat certain forms of non-Hodgkin's lymphoma. It is usually given after other...

  • Tositumomab - an overview | ScienceDirect Topics

    Tositumomab complexes 131 Iodine to the anti-B1 antibody and has been studied extensively in the treatment of heavily pretreated, 83 untreated, 84 and for retreatment of indolent lymphomas. 85 Best responses are seen in previously untreated patients with FL treated with a single treatment course with tositumomab in whom there was a 95% OR, 75% ...

  • Tositumomab I 131 - Drugs and Lactation Database (LactMed ...

    Dec 03, 2018· Information in this record refers to the use of tositumomab I 131 as a therapeutic agent. No information is available on the use of tositumomab I 131 during breastfeeding. Because of the potential for serious adverse reactions in nursing infants, the manufacturer and expert opinion recommend not administering the drug in women who wish to continue breastfeeding.[1]

  • Iodine I 131 tositumomab - AdisInsight

    Iodine I 131 tositumomab is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen, which is found specifically on B

  • Tositumomab I 131 - an overview | ScienceDirect Topics

    Oct 24, 2005· Iodine-131 Tositumomab (Iodine-131 Bexxar) I-131 tositumomab (I-131 Bexxar) is a murine IgG2a monoclonal antibody developed to target CD20, which is the same target for Y-90 ibritumomab tiuxetan. Y-90 ibritumomab tiuxetan and I-131 tositumomab …

  • The Commercial Withdrawal of Tositumomab

    In the fall of 2013, GlaxoSmithKline (GSK) withdrew its drug tositumomab (Bexxar) for marketing reasons. An anticancer radioantibody conjugate of iodine I 131, tositumomab consisted of an anti-CD20 antibody covalently linked to radioactive iodine I 131. The drug targeted cells expressing CD20 and delivered a local dose of γ- and β-radiation.

  • Tositumomab and Iodine I 131 Tositumomab (Other Names ...

    Tositumomab and Iodine I - 131 is another name for Tositumomab. In some cases, health care professionals may use the trade name Bexxar or other name Tositumomab and Iodine I - 131 when referring to the generic drug name Tositumomab. Drug type: Tositumomab is a monoclonal antibody that is linked with a radioactive atom Iodine - 131. (For more ...

  • Tositumomab - Wikipedia

    Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, produced in mammalian cells. Combined with radioisotope iodine 131 it was called Iodine I 131 Tositumomab.Unlabelled tositumomab together with iodine-labelled tositumomab was called Bexxar and a personalized regimen using Bexxar was approved for the treatment of relapsed or …

  • Radioimmunotherapy with tositumomab and iodine-131 ...

    I-131 Tositumomab is an iodine-131 labeled anti-CD20 murine IgG2a monoclonal antibody and is one of two FDA-approved radioimmunotherapeutic drugs for patients with non-Hodgkin’s lymphoma (NHL). For more than a decade now, radiolabeled tositumomab has principally been evaluated in low-grade and transformed low-grade NHL patients with proven ...

  • Iodine-131 tositumomab (Bexxar) in a radiation oncology ...

    Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin's lymphoma. The compound itself is formulated as ...

  • R-CHOP, radioimmunotherapy, and maintenance rituximab in ...

    Jan 24, 2018· GlaxoSmithKline provided the drug, 131 iodine tositumomab, and provided financial support for expenses associated with the cost of nuclear medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the views of GlaxoSmithKline.

  • Reference ID: 3174958

    BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directed radiotherapeutic antibody indicated for the treatment of patients with CD20­ positive, relapsed or refractory, low-grade, follicular, or transformed non­ Hodgkin's lymphoma who have progressed during or after rituximab therapy,

  • Tositumomab and Iodine I 131 Tositumomab (Bexaar ...

    Iodine I-131 tositumomab is a well tolerated and effective therapy for recurrent low-grade and transformed low-grade non-Hodgkin lymphoma (NHL). Hematologic reserve …

  • Radioactive Iodine 131 (I-131) | Stony Brook Cancer Center

    Radioactive Iodine 131 (I-131) You will receive radioiodine because you and your doctor have agreed that this is the most appropriate treatment for your thyroid cancer. Special precautions will be taken to protect you and the hospital staff caring for you, to prevent or limit the amount of exposure to a radioactive source.

  • 131I-Tositumomab Therapy as Initial Treatment for ...

    Feb 03, 2005· The actions of tositumomab and 131 I-labeled tositumomab (registered as Tositumomab and Iodine I 131 Tositumomab [the Bexxar therapeutic …

  • Label - Tositumomab and Iodine I 131 Tositumomab …

    46 Iodine I 131 Tositumomab 47 Iodine I 131 Tositumomab is a radio -iodinated derivat ive of Tositumomab 48 that has been covalently linked to Iodine-131. Unbound radio-iodine and 49 other reactants have been removed by chromatographic purification steps. 50 Iodine I 131 Tositumomab is supplied as a sterile, clear, preservative -free

  • Comparison Of Rituximab Versus Tositumomab and Iodine I ...

    Dec 23, 2005· Comparison of rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab or the Bexxar Therapeutic Regimen, formerly called Iodine-131 Anti-B1 Antibody) in subjects with follicular non Hodgkins B cell lymphoma. 506 subjects will be enrolled at 30 to 40 sites in the US, Canada, and Europe.

  • Tositumomab & I-131 (Bexxar) | HemOnc.org - A Hematology ...

    General information. Class/mechanism: Radioimmunotherapy; treatment regimen that includes two separate steps: first, a dosimetric dose with an anti-CD20 antibody (tositumomab) alone, and second, a therapeutic dose with tositumomab bound to a radioactive isotope, iodone-131 (I-131).

  • Definition of iodine I 131 tositumomab - NCI Drug ...

    A monoclonal antibody directed against the CD20 protein expressed on the surface of B-lymphocytes and radiolabeled with the radioisotope iodine I 131 with potential antineoplastic activity. Iodine I 131 tositumomab binds to and selectively delivers cyctotoxic radiation to CD20-expressing B-lymphocytes, thereby minimizing systemic radiotoxicity.